Toxic vacuolation

Fierce Biotech Names Synthekine as One of Its “Fierce 15” Biotech Companies of 2022

Retrieved on: 
Monday, September 12, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, Fierce, Cytokine, Twitter, Inflammation, FDA, Creativity, LinkedIn, Inc., Face, News, Partnership, Industry, Program, Patient, Cancer, CD19, Technology, Toxic vacuolation, Biotechnology, Drug discovery, Pharmaceutical industry, Vaccine

Synthekine Inc. , an engineered cytokine therapeutics company, today announced that Fierce Biotech has named it as one of 2022s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Key Points: 
  • Synthekine Inc. , an engineered cytokine therapeutics company, today announced that Fierce Biotech has named it as one of 2022s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
  • I am particularly proud of the substantial progress our talented and dedicated team has made in the three years since Synthekine was founded.
  • The Fierce 15 celebrates the spirit of being fierce championing innovation and creativity, even in the face of intense competition.
  • More than 450,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories.

Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform

Retrieved on: 
Monday, November 1, 2021
Biotechnology, Pharmaceutical, Health, MSD, Research, Cytokine, Cancer, Protein engineering, Merck, Merck & Co., View, Inflammation, Inc., Degenerative disease, Maintenance, Therapy, Toxic vacuolation, Pharmaceutical industry, Vaccine

The collaboration will leverage Synthekines proprietary surrogate cytokine agonist platform to discover, develop, and commercialize novel cytokine therapeutics.

Key Points: 
  • The collaboration will leverage Synthekines proprietary surrogate cytokine agonist platform to discover, develop, and commercialize novel cytokine therapeutics.
  • Our surrogate cytokine agonist platform produces a new class of cytokine therapeutics that are designed to deliver selective immunotherapies for the treatment of autoimmune diseases and cancer, said Debanjan Ray, chief executive officer of Synthekine.
  • We are thrilled to announce our first collaboration using this platform with an unequivocal leader in the field.
  • Under the terms of the agreement, Synthekine is responsible for initial research efforts in collaboration with Merck, and Merck will have exclusive rights to develop, manufacture and commercialize surrogate cytokine agonists for up to two cytokine targets.

Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors

Retrieved on: 
Thursday, October 28, 2021
Research, FDA, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Death, Cancer, Capillary leak syndrome, Cytokine, FDA, Inflammation, Food, Inc., Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CLS, IND, Therapy, Toxicity, Toxic vacuolation, AACR, Pharmaceutical industry, Vaccine

The study will investigate STK-012 both as a monotherapy and in combination with an immune checkpoint inhibitor in individuals with advanced solid tumors.

Key Points: 
  • The study will investigate STK-012 both as a monotherapy and in combination with an immune checkpoint inhibitor in individuals with advanced solid tumors.
  • However, the indiscriminate activity of IL-2 can cause severe toxicities, limiting its clinical application, said Naiyer Rizvi, M.D., chief medical officer of Synthekine.
  • Synthekine is harnessing the potential of cytokine therapeutics to develop selective immunotherapies designed to improve the treatment paradigm of cancer and inflammatory disease.
  • Synthekine is applying principles of cytokine partial agonism and immunological specificity across multiple protein engineering platforms to create a broad and deep pipeline of product candidates.